• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • The Amended Drug Administration Law

The Amended Drug Administration Law

Friday, 20 September 2019 / Published in News, Pharmaceuticals & DMF

The Amended Drug Administration Law

On August 26, 2019, the China’s National People’s Congress passed The Amended Drug Administration Law (the Amended DAL) which will go into effect on 01.12.2019. The revised law establishes strict standards and measures in supervision over the whole process of the pharmaceutical industry chain in order to address prominent problems within research and development, manufacturing, sales, management and use of drugs.

The first DAL was released in 1984. This is the first revision since 2001. The new law brings in some changes while consolidating many existing practices, indluding:

– Redefining the scope of counterfeit and inferior drugs
Note: The new definition of counterfeit drugs focuses the definition on active ingredients and claims. Unapproved drugs are not regarded as counterfeit anymore.

– Implementing an improved national Drug Market Authorization Holder (“MAH”) system, including database
Note: foreign pharmaceutical companies are required to appoint a Legal Agent in China, who will need to assume the same regulatory obligations and liability as the foreign MAH.

– Deepening E-pharmacy regulation
Note: the new DAL takes a more lenient approach to online sale of prescription drugs, which must satisfy separate regulations to be issued by the NMPA. High-risk pharmaceutical products are excluded.

– Supporting drug innovation by reforming the drug approval system
Note: certain rules proposed in a pervious draft, which were in favour of innovative pharmaceuticals (including data exclusivity, patent linkage, and the acceptance of foreign clinical trial data for approval) are absent in the Amended DAL.

– Product liability and severe penalties against violation

Tagged under: Drug Administration Law, drugs, MAH, pharmaceutical

What you can read next

2 Health Food Products Draft Regulations Issued for Public Consultation
cosmetics adverse reactions collection and reporting
Cosmetics adverse reactions collection and reporting guidelines for registrants and filers (Trial) – Draft issued
UDI Database of NMPA: Understand It Within 6 Minutes

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Physicochemical characterization of nanomaterials

    Physicochemical characterization of nanomaterials used in medical devices – New guidelines issued

    Physicochemical characterization of nanomateria...
  • Registration of disposable light-proof infusion sets in China

    Registration of disposable light-proof infusion sets in China – Amended guidelines issued

    Registration of disposable light-proof infusion...
  • Registration of disposable blood separation devices in China

    Registration of disposable blood separation devices in China – Amended guidelines issued

    Registration of disposable blood separation dev...
  • Registration of disposable infusion devices in China

    Registration of disposable infusion devices in China – Amended guidelines issued

    Registration of disposable infusion devices in ...
  • Registration of blood dialyzers in China

    Registration of blood dialyzers in China – Amended guidelines issued

    Registration of blood dialyzers in China shall ...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP